Abstract
Gemcitabine is a cytosine arabinoside(Ara-C) analog with activity in many humantumor systems. We evaluated the drug'sactivity in resistant or relapsing multiplemyeloma. Gemcitabine 1000 mg/m2 wasadministered as a 30 minute infusion ondays 1, 8, and 15 of a 28-day cycle. Nodose escalations were permitted and dosereductions were scheduled for hematologictoxicity. Twenty-nine eligible patientswere entered into Southwest Oncology Group(SWOG)-9803. One patient received notreatment and 5 patients had inadequateresponse assessments. The major toxicitywas hematologic with grade 3/4 neutropeniain 9 and grade 3/4 thrombocytopenia in 15patients. No responses were seen. Stabledisease was confirmed in sixteen patients(57%). Median survival was eight months. Gemcitabine as utilized in this trial hasshown little activity and is not to bestrongly considered for future multiplemyeloma trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
SEER Cancer Statistics Review: 1973–1990. Bethesda, NCI, 1993
Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics 1999. CA Cancer J Clin 49(1): 8–31, 1999
Bataille R, Harousseau JL: Multiple myeloma. N Engl J Med 336: 1657–1664, 1997
Kyle R: Long term survival in multiple myeloma. N Engl J Med 19: 314–318, 1978
Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 7: 484–489, 1994
Buzaid AC, Durie BGM. Management of refractory myeloma: a review. J Clin Oncol 6: 889–908, 1998
Kraut E, Crowley J, Wade J, Laufman L, Alsina A, Taylor S, Salmon S: Evaluation of Topotecan in Resistant and Relapsed Multiple Myeloma: A Southwest Oncology Group Study. J Clin Oncol 16(2): 589–592, 1998
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandi V. Gemcitabine metabolism, mechanics of action, and self-potentiation. Semin Oncol 22: 3–10, 1995
Huang P, Plunkett W. Fludarabine-and gemcitabine-induced apoptosis: incorporation of analogs into DNA is critical event. Cancer Chemother Pharmacol 36: 181–188, 1995
Hertel LW, Boser GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417–4422, 1990
Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, Grindey GB, Von Hoff DD: Activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anti-Cancer Drugs 3: 143–146, 1992
Poplin EA, Corbett T, Flaherty L, Tarasoff P, Redman BG, Valdivieso M, Baker L: Difluorodeoxycytidine (dFdC, gemcitabine): A phase I study. Invest New Drugs 10: 165–170, 1992
Burris HA, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, and Von Hoff DD: Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. A randomized trial. J Clin Onc 15: 2403–2413, 1997
Sorensen JB: Gemcitabine in non-small cell lung cancer. Lung Cancer 12Suppl 1: S173–S175, 1995
Lund B, Hansen OP, Theilade K, Hansen M Nejit JP: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Nat Canc Inst 86: 1530–1533, 1994
Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer: A Phase II trial with gemcitabine. J Clin Oncol 13: 2731–2736, 1995
Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J: A Phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5: 543–547, 1994
Niyikiza C, Anderson JS, Tarassoff PG, Rothenberg ML, Seitz DE, Nelson RL, Moore M, Storniolo AM: Prognostic factors in a randomized trial of Gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer and in pancreatic cancer patients failing 5-FU who received gemcitabine as a palliative therapy. Proc Am Soc Clin Oncol 15: 506, 1996
Zinzani PL, Baliva G, Magagnoli M, Bendand M, Modugno G, Gherlinzoni F, Orcioni GF, Ascani S, Simoni R, Pileri SA, Tura S: Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18: 2603–2606, 2000
Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G and Diehl V: Gemcitabine in the treatment in refractory Hodgkin's disease: Results of a Phase II study. J Clin Oncol 18: 2615–2619, 2000
Gemcitabine HCl (LY188011 HCl): Clinical Investigation Brochure. Indianapolis, Ely Lilly & Co., 1993
Green MR: Gemcitabine safety overview. Semin Oncol 23: 32–35, 1996
Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16: 3832–3842, 1998
Folkman J: Clinical application of research on angiogenesis. N Engl J Med 333: 1757–1763, 1995
Munshi NC, Barlogie B, Desikan KR and Wilson C: Novel Approaches in Myeloma Therapy. Semin Oncol 26(suppl 13): 28–34, 1999
Bahlis NJ, Grad JF, Fernandez HF, Lee KP, Boise LH: Arsenic trioxide and ascorbic acid induced apoptosis in primary myeloma cells from chemo-resistant patients. Blood 96:#11, 160a, 2000
Weiss RB: New sources and new antitumor drugs in development. Semin Oncol 24(2): 153–155, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weick, J.K., Crowley, J.J., Hussein, M.A. et al. The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: a Southwest Oncology Group Study. Invest New Drugs 20, 117–121 (2002). https://doi.org/10.1023/A:1014493007347
Issue Date:
DOI: https://doi.org/10.1023/A:1014493007347